Anti-aging Technologies Based on Real Science and Developed by Real Scientists

ReBeaut” – Initial Program Focused on “Rebooting” the Skin’s Genetic Program to Fight Cancer and Restore Youthful Beauty

Ponce Therapeutics is leveraging the growing scientific knowledge surrounding the process of aging to develop its first state-of-the-art biotechnology platform to restore the youthful balance of aged or “senescent” and young cells in the skin, targeting the senescent cells for elimination. This provides a “reboot” of one’s genetic program to turn the clock on one’s skin back to its youthful exuberance.

Proprietary Platform

Targeting Senescent Cells for Elimination

Elimination of pro-inflammatory senescent cells has been shown to suppress cancer and rejuvenate tissues by restoring stem cell niches to their healthy state.

Ponce Therapeutics Gene Therapy

Clinical Pipeline

Development of our lead program, PT-001mn

Lead program, PT-001mn, to deliver p16-directed riCasp9 to keratinocytes in treating Bowen’s lesions using proprietary delivery technology.

February 8, 2021 in Ponce Therapeutics, Portfolio, Rapha Capital Management

Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin

Rapha Capital Management Leads Convertible Note Financing Miami, FL – February 8, 2021 - Ponce Therapeutics, Inc. (“Ponce”), a company leveraging the growing scientific knowledge surrounding the aging process to…
Read More